Literature DB >> 21458312

Outcomes of Korean patients with clinically localized urachal or non-urachal adenocarcinoma of the bladder.

Sung Yong Cho1, Kyung Chul Moon, Ji-Hyun Park, Cheol Kwak, Hyeon Hoe Kim, Ja Hyeon Ku.   

Abstract

OBJECTIVE: This study aimed to investigate whether there is a difference between clinically localized urachal and non-urachal adenocarcinomas in terms of patient survival.
METHODS: A total of 31 patients without evidence of distant metastasis who were treated by radical or partial cystectomy were included in the study. Of the 31 cases, 17 and 14 fulfilled the histologic criteria for urachal and non-urachal carcinoma, respectively. The mean follow-up period was 54.2 months (range: 6.6-188.8).
RESULTS: Patients with urachal adenocarcinoma were significantly younger than patients with non-urachal adenocarcinomas (45.7 vs. 70.0 years; P = 0.002). The rates of local or distant recurrence were similar (47.1 vs. 50.0%; P = 0.507, log-rank test). Patients with ≤ 4-cm tumors had a better disease-free survival than those with >4-cm tumors (P = 0.043, log-rank test). Patients with mucinous type adenocarcinoma tended to have better disease-free survival than those with other histologic types of adenocarcinoma (P = 0.064, log-rank test). Multivariate Cox regression analysis revealed that only tumor size and histologic type could predict the disease-free survival after surgery of patients with primary adenocarcinoma.
CONCLUSIONS: Our findings suggest that the disease-free survivals associated with urachal and non-urachal adenocarcinoma do not differ significantly but that attempts should be made to diagnose these aggressive tumors early, when they are more likely to be small, since the survivors without disease after surgery appear to be patients in whom the tumor was small.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21458312     DOI: 10.1016/j.urolonc.2010.10.002

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  5 in total

1.  Survival of Patients With UrAC and Primary BAC and Urothelial Carcinoma With Glandular Differentiation.

Authors:  Tao Wang; Zheng Lv; Huayi Feng; Jinlong Li; Bo Cui; Yang Yang; Xing Huang; Xiangyi Zhang; Xintao Li; Xin Ma
Journal:  Front Oncol       Date:  2022-05-12       Impact factor: 5.738

2.  Primary adenocarcinoma of the renal pelvis, ureter and the urinary bladder: A case report and review of the literature.

Authors:  Xing Xiong; Linghua Jia; Jingen Wang
Journal:  Oncol Lett       Date:  2016-01-26       Impact factor: 2.967

3.  Prognostic factors for urachal cancer: a bayesian model-averaging approach.

Authors:  In Kyong Kim; Joo Yong Lee; Jong Kyou Kwon; Jae Joon Park; Kang Su Cho; Won Sik Ham; Sung Joon Hong; Seung Choul Yang; Young Deuk Choi
Journal:  Korean J Urol       Date:  2014-09-05

4.  Mucinous adenocarcinoma of the urinary bladder.

Authors:  Giulio Baffigo; Giampaolo Delicato; Daniele Bianchi; Stefano Signore; Edoardo Tartaglia; Francesco Corvese; Alessandro Perla; Bonaventura Marino; Giuseppe Santeusanio; Vincenzo Ferdinandi
Journal:  Am J Case Rep       Date:  2012-06-05

Review 5.  Biomarkers in Urachal Cancer and Adenocarcinomas in the Bladder: A Comprehensive Review Supplemented by Own Data.

Authors:  Henning Reis; Ulrich Krafft; Christian Niedworok; Orsolya Módos; Thomas Herold; Mark Behrendt; Hikmat Al-Ahmadie; Boris Hadaschik; Peter Nyirady; Tibor Szarvas
Journal:  Dis Markers       Date:  2018-03-12       Impact factor: 3.434

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.